Benjamin A Steinberg1, Sana M Al-Khatib1, Rex Edwards2, JooYoon Han3, Gust H Bardy4, J Thomas Bigger5, Alfred E Buxton6, Arthur J Moss7, Kerry L Lee2, Richard Steinman8, Paul Dorian9, Alfred Hallstrom3, Riccardo Cappato10, Alan H Kadish11, Peter J Kudenchuk12, Daniel B Mark1, Lurdes Y T Inoue3, Gillian D Sanders13. 1. Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Duke University, Durham, North Carolina. 2. Duke Clinical Research Institute, Duke University, Durham, North Carolina. 3. Department of Biostatistics, University of Washington, Seattle, Washington. 4. Seattle Institute for Cardiac Research, Seattle, Washington; Division of Cardiology, University of Washington, Seattle, Washington. 5. Department of Medicine, Columbia University, New York, New York. 6. Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 7. Heart Research Follow-up Program, University of Rochester Medical Center, Rochester, Minnesota. 8. Irving Institute for Clinical and Translational Research, Columbia University, New York, New York. 9. Departments of Medicine and Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. 10. I.R.C.C.S. Policlinico San Donato, Milan, Italy. 11. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 12. Division of Cardiology, University of Washington, Seattle, Washington. 13. Duke Clinical Research Institute, Duke University, Durham, North Carolina. Electronic address: gillian.sanders@duke.edu.
Abstract
OBJECTIVES: The aim of this study was to determine if the benefit of implantable cardioverter-defibrillators (ICDs) is modulated by medical comorbidity. BACKGROUND: Primary prevention ICDs improve survival in patients at risk for sudden cardiac death. Their benefit in patients with significant comorbid illness has not been demonstrated. METHODS: Original, patient-level datasets from MADIT I (Multicenter Automatic Defibrillator Implantation Trial I), MADIT II, DEFINITE (Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation), and SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) were combined. Patients in the combined population (N = 3,348) were assessed with respect to the following comorbidities: smoking, pulmonary disease, diabetes, peripheral vascular disease, atrial fibrillation, ischemic heart disease, and chronic kidney disease. The primary outcome was overall mortality, using the hazard ratio (HR) of time to death for patients receiving an ICD versus no ICD by extent of medical comorbidity, and adjusted for age, sex, race, left ventricular ejection fraction, use of antiarrhythmic drugs, beta-blockers, and angiotensin-converting enzyme inhibitors. RESULTS: Overall, 25% of patients (n = 830) had <2 comorbid conditions versus 75% (n = 2,518) with significant comorbidity (≥2). The unadjusted hazard of death for patients with an ICD versus no ICD was significantly lower, but this effect was less for patients with ≥2 comorbidities (unadjusted HR: 0.71; 95% confidence interval: 0.61 to 0.84) compared with those with <2 comorbidities (unadjusted HR: 0.59; 95% confidence interval: 0.40 to 0.87). After adjustment, the benefit of an ICD decreased with increasing number of comorbidities (p = 0.004). CONCLUSIONS: Patients with extensive comorbid medical illnesses may experience less benefit from primary prevention ICDs than those with less comorbidity; implantation should be carefully considered in sick patients. Further study of ICDs in medically complex patients is warranted.
OBJECTIVES: The aim of this study was to determine if the benefit of implantable cardioverter-defibrillators (ICDs) is modulated by medical comorbidity. BACKGROUND: Primary prevention ICDs improve survival in patients at risk for sudden cardiac death. Their benefit in patients with significant comorbid illness has not been demonstrated. METHODS: Original, patient-level datasets from MADIT I (Multicenter Automatic Defibrillator Implantation Trial I), MADIT II, DEFINITE (Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation), and SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) were combined. Patients in the combined population (N = 3,348) were assessed with respect to the following comorbidities: smoking, pulmonary disease, diabetes, peripheral vascular disease, atrial fibrillation, ischemic heart disease, and chronic kidney disease. The primary outcome was overall mortality, using the hazard ratio (HR) of time to death for patients receiving an ICD versus no ICD by extent of medical comorbidity, and adjusted for age, sex, race, left ventricular ejection fraction, use of antiarrhythmic drugs, beta-blockers, and angiotensin-converting enzyme inhibitors. RESULTS: Overall, 25% of patients (n = 830) had <2 comorbid conditions versus 75% (n = 2,518) with significant comorbidity (≥2). The unadjusted hazard of death for patients with an ICD versus no ICD was significantly lower, but this effect was less for patients with ≥2 comorbidities (unadjusted HR: 0.71; 95% confidence interval: 0.61 to 0.84) compared with those with <2 comorbidities (unadjusted HR: 0.59; 95% confidence interval: 0.40 to 0.87). After adjustment, the benefit of an ICD decreased with increasing number of comorbidities (p = 0.004). CONCLUSIONS:Patients with extensive comorbid medical illnesses may experience less benefit from primary prevention ICDs than those with less comorbidity; implantation should be carefully considered in sick patients. Further study of ICDs in medically complex patients is warranted.
Authors: David T Huang; Henry W Sesselberg; Scott McNitt; Katia Noyes; Mark L Andrews; W Jackson Hall; Andrew Dick; James P Daubert; Wojciech Zareba; Arthur J Moss Journal: J Cardiovasc Electrophysiol Date: 2007-05-30
Authors: Ilan Goldenberg; Arthur J Moss; Scott McNitt; Wojciech Zareba; Mark L Andrews; W Jackson Hall; Henry Greenberg; Robert B Case Journal: Am J Cardiol Date: 2006-06-19 Impact factor: 2.778
Authors: Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip Journal: N Engl J Med Date: 2005-01-20 Impact factor: 91.245
Authors: Michael A Brodsky; John McAnulty; Douglas P Zipes; Christina Baessler; Alfred P Hallstrom Journal: Am Heart J Date: 2006-10 Impact factor: 4.749
Authors: Douglas S Lee; Jack V Tu; Peter C Austin; Paul Dorian; Raymond Yee; Alice Chong; David A Alter; Andreas Laupacis Journal: J Am Coll Cardiol Date: 2007-06-11 Impact factor: 24.094
Authors: Christine M Albert; Rebecca Quigg; Samir Saba; N A Mark Estes; Andi Shaechter; Haris Subacius; Adam Howard; Joseph Levine; Alan Kadish Journal: Am Heart J Date: 2008-08 Impact factor: 4.749
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Paul S Chan; Brahmajee K Nallamothu; John A Spertus; Frederick A Masoudi; Cheryl Bartone; Dean J Kereiakes; Theodore Chow Journal: Circ Cardiovasc Qual Outcomes Date: 2009-01-06
Authors: Alexandra M Hajduk; Jerry H Gurwitz; Grace Tabada; Frederick A Masoudi; David J Magid; Robert T Greenlee; Sue Hee Sung; Andrea E Cassidy-Bushrow; Taylor I Liu; Kristi Reynolds; David H Smith; Frances Fiocchi; Robert Goldberg; Thomas M Gill; Nigel Gupta; Pamela N Peterson; Claudio Schuger; Humberto Vidaillet; Stephen C Hammill; Heather Allore; Alan S Go Journal: J Am Geriatr Soc Date: 2019-03-20 Impact factor: 5.562
Authors: Teresa L Rogstad; Adam C Powell; Yongjia Song; Tristan Cordier; Stephen E Price; James W Long; Uday U Deshmukh; Jeffrey D Simmons Journal: Clin Cardiol Date: 2018-09-20 Impact factor: 2.882
Authors: Aaron M Hein; Julia J Scialla; Daniel Edmonston; Lauren B Cooper; Adam D DeVore; Robert J Mentz Journal: JACC Heart Fail Date: 2019-05 Impact factor: 12.035
Authors: Georges N Nakhoul; Jesse D Schold; Susana Arrigain; Serge C Harb; Stacey Jolly; Bruce L Wilkoff; Joseph V Nally; Sankar D Navaneethan Journal: Clin J Am Soc Nephrol Date: 2015-06-25 Impact factor: 8.237
Authors: Daniel J Friedman; Sana M Al-Khatib; Emily P Zeitler; JooYoon Han; Gust H Bardy; Jeanne E Poole; J Thomas Bigger; Alfred E Buxton; Arthur J Moss; Kerry L Lee; Richard Steinman; Paul Dorian; Riccardo Cappato; Alan H Kadish; Peter J Kudenchuk; Daniel B Mark; Lurdes Y T Inoue; Gillian D Sanders Journal: Am Heart J Date: 2017-06-09 Impact factor: 4.749
Authors: Ashok Krishnaswami; Mary-Lou Kiley; Faith F Anthony; Yuexin Chen; Jason Chen; Sumanth Rajagopal; Taylor I Liu; Charlie Young; Elizabeth W Paxton Journal: Perm J Date: 2015-11-02